How the WeighScore Is Calculated

A grade is only as trustworthy as the formula behind it. So here is ours, in full — the six dimensions, their weights, how they roll up into a single 0–100 WeighScore, and the rules that keep the number honest. If you would rather see it as a reference table, the full methodology lays out every weight side by side.

One formula, every provider

The WeighScore is not a vibe. Every provider is scored 0–100 on the same six dimensions, with the same weights, and mapped to the same letter scale. There is no bonus lane for providers we like and no penalty box for ones we do not. Same rubric, same math, every time — that consistency is what makes two grades actually comparable.

The six dimensions and their weights

**Cost value — 25%.** The heaviest weight, because price is where providers most often mislead. We score the normalized cost of an equivalent maintenance dose, and how it moves after any introductory period. Hidden step-ups cost points. Our guide to what compounded GLP-1 costs per month shows the normalization we run. Sometimes normalization is impossible and the company stays ungraded: we could not score Pepti, because a dormant per-dose ladder sits behind its flat-price headline and the checkout that would settle which one bills is unreachable.

**Dose and formulation — 20%.** Breadth of molecules, titration flexibility, and route options. This matters because the molecules are not interchangeable: once-weekly semaglutide 2.4 mg produced a mean −14.9% body-weight change in the STEP-1 trial¹, while tirzepatide reached up to about −20.9% in SURMOUNT-1². A provider that stocks both molecules and a full titration ladder can follow the evidence; one that stocks a single dose cannot. We unpack the trade-off in semaglutide vs. tirzepatide.

**Clinical oversight — 20%.** Prescriber model, provider verification confidence, and how care is supervised and escalated. This is the safety backbone of the score — and it matters more than a first-month intake suggests, since the trial record now shows these drugs affecting more than weight; see what else GLP-1 drugs do, beyond weight loss for what a prescriber should actually understand.

**Labs and monitoring — 15%.** Whether baseline labs, ongoing check-ins, and side-effect monitoring are included or sold as extras — including whether a provider tracks body composition, not just the scale, since a real share of GLP-1 weight loss is lean mass; see does semaglutide or tirzepatide cause muscle loss? A real intake also asks about factors like alcohol use, where the trial evidence is newer than most providers' forms account for.

**Fulfillment — 12%.** Pharmacy sourcing transparency, shipping reliability, and cold-chain handling — including whether a provider will tell you which pharmacy fills your prescription.

**Contract terms — 8%.** Cancellation friction, refund posture, auto-renewal honesty, and lock-in. Small weight, real consequences — Rehydra+ Wellness advertises GLP-1 memberships from $119 a month, and every one of them is a six-month non-cancelable commitment of $714 or more.

How the dimensions become one number

Each dimension is scored 0–100 on its own merits. We then multiply each dimension score by its weight and sum the results into a single weighted 0–100 WeighScore. Because the weights total 100%, a provider that is merely average everywhere lands mid-pack, while a standout on cost value moves more than a standout on contract terms — by design, since the weights encode how much each factor matters to a real buyer.

From score to letter grade

The WeighScore maps to a letter: A (93+), A− (90–92), B+ (87–89), B (83–86), B− (80–82), C+ (77–79), and C (below 77). A grade is a relative read on today's market — not a safety rating and not medical advice. A high grade means a provider compares well right now, not that it is right for you.

What never moves the number

Affiliate relationships. A provider that pays us a commission runs through the exact same rubric as one that does not, and a weak provider is graded low regardless of any partnership. The scoring function has no input for who pays; it can only read the six factor marks. Nor does the write-up soften — an unflattering finding about a provider we earn from stays in, and where the evidence behind a claim is thin we say so. The full detail lives in our disclosure, the reference weights in the methodology, and the standing rules we hold every write-up to in our editorial policy — which also names who we are and how this site makes money.

Facts change; the formula does not

Provider pricing, dosing menus, and terms move constantly, so grades are re-scored as the facts change. The one thing that stays fixed is the formula. That is the point of a scorecard: when the inputs shift, you can trust that only the inputs shifted. See the formula applied across the market in our reviews and comparisons, or watch it broken open row by row on the graded tirzepatide ranking, which prints every factor, its weight and the points it contributes. Every published ranking is indexed on the rankings page.